menu

KDIGO Conversations in Nephrology: Approaches to RASi Optimization

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

KDIGO Conversations in Nephrology: Approaches to RASi Optimization

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Covered in this conversation is Dr. Rossignol’s personal approach to RASi optimization and monitoring of creatinine and potassium. Also discussed are recommendations for clinicians based on the latest guidelines.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Patrick Rossignol, MD, PhD
    Nephrologist, Professor of Therapeutics
    Medical Director
    Centre d’Investigation Clinique Inserm (CIC)
    Nancy, France

    Contracted Research: Vifor Pharma
    Ownership Interest: CardioRenal, G3P 
    Patent Holder: CardioRenal
    Consulting Fees/Advisory Board: AstraZeneca, Bayer, Boehringer Ingelheim, KBP, Novartis, Novo-Nordisk, Sequana Medical, Vifor Pharma
    Commercial Interest Speakers Bureau: AstraZeneca, Novartis, Sanofi, Vifor Pharma

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Covered in this conversation is Dr. Rossignol’s personal approach to RASi optimization and monitoring of creatinine and potassium. Also discussed are recommendations for clinicians based on the latest guidelines.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Patrick Rossignol, MD, PhD
    Nephrologist, Professor of Therapeutics
    Medical Director
    Centre d’Investigation Clinique Inserm (CIC)
    Nancy, France

    Contracted Research: Vifor Pharma
    Ownership Interest: CardioRenal, G3P 
    Patent Holder: CardioRenal
    Consulting Fees/Advisory Board: AstraZeneca, Bayer, Boehringer Ingelheim, KBP, Novartis, Novo-Nordisk, Sequana Medical, Vifor Pharma
    Commercial Interest Speakers Bureau: AstraZeneca, Novartis, Sanofi, Vifor Pharma

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Schedule19 Oct 2021